Navigation Links
Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
Date:2/12/2008

ALLEGAN, Mich., Feb. 12 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for over-the-counter Famotidine 10 mg, Calcium Carbonate 800 mg, and Magnesium Hydroxide 165 mg, Chewable Tablets.

The product will be marketed under store brand labels and is comparable to Johnson & Johnson - Merck Consumer Pharmaceutical's Pepcid(R) Complete, an acid reducer plus antacid medication indicated for the relief of heartburn associated with acid indigestion and sour stomach. Annual retail sales for Pepcid Complete chewable tablets are estimated to be approximately $95 million.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This final approval reflects our continuing investment in new products. As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders."

Perrigo was the first applicant to file a complete ANDA with a Paragraph IV certification and we expect to have marketing exclusivity. The Company expects to begin shipping the product in the third quarter of calendar 2008.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2007, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... Charlotte, NC (PRWEB) , ... December 08, 2016 ... ... repeal Medicare and the Affordable Care Act. Dr. Botelho advocates for the mass ... A story movement gives people ongoing opportunities to share their unfortunate experiences; such ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... services from offices headquartered in Jefferson County, is announcing the launch of a ... Birmingham. , The number of homeless women and children in Birmingham has grown ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a locally ... commercial clients in the northern Alabama and Georgia regions, is embarking on a ... Nobis Works has built a network of support and education facilities to develop ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX , ... Nationwide Children,s Hospital signed a membership agreement ... the development of new cures. The ... over 57 million patients globally, biopharmaceutical companies and ... to improve protocol design, site selection, patient recruitment, ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: